Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10658820 | 0.98 | MEN1 (0.54) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL22215903 | 0.93 | MAPT (0.63) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL8428065 | 0.82 | PTPRC (0.58) | KMT2AMEN1LMNASMN1; SMN2PTPRC | |
| SCHEMBL7989609 | 0.81 | MEN1 (0.56) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL3434413 | 0.79 | MEN1 (0.54) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL10887519 | 0.78 | MAPT (0.67) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL10347244 | 0.77 | KMT2A (0.88) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9240977 | 0.77 | MAPT (0.44) | MAPTKMT2AMEN1ADORA2ACHRNA7 | |
| SCHEMBL9148081 | 0.77 | MAPT (0.55) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL577828 | 0.76 | ADRA2A (0.54) | MAPTKMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8222203-B2 | Macrocyclic oximyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222203-B2 | Macrocyclic oximyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009117594-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009079352-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, HPN, PRSS1 | MAPT 4520/4885KMT2A 2340/4885MEN1 4233/4885 |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, SPINT2, CTSV | MAPT 4301/4885KMT2A 2790/4885MEN1 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.